The Geneva-based biotechnology group, Serono, has been given European Union approval for its multiple sclerosis (MS) drug, Rebif.
The company said the EU had also recommended the treatment as a first-line therapy for patients with relapsing-remitting MS, the most common form of the disease.
Serono said the Commission's approval was based on a four-year study, which provided clinical evidence that a high dose of Rebif administered as early as possible after the onset of the disease "significantly improves the long-term outlook for the patient".
Serono said Rebif is the only interferon beta product to have gained full approval by the Commission.
The company also announced that it had launched two fertility products in the United States,Ovdrel and Cetrotide.
swissinfo with agencies